WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds
--------------------------------------------------------------------
Source: South China Morning Post
Published: 2026-08-25 23:03 UTC+10:00
Section: WuXi Biologics
Factuality Score: 100
Opinion Category: Neutral
Topics: Business, Health, Asia, China, Financial Markets, Drugs, Business & Economy, Asia Pacific
--------------------------------------------------------------------
Snippet:
Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance
--------------------------------------------------------------------